### Bowel problems after treatment of colon cancer



Søren Laurberg
Professor of Surgery
Aarhus University Hospital
Denmark

## Bowel problem CRC

- RECTAL CANCER : YES
  - LARS
  - STOMA
- COLON CANCER: ?????

### **CHALLENGE**

#### CRC treatment bowel function

Patients often have symptoms due to cancer

Symptoms common in the general Population

- Symptoms after treatment
  - Symptoms due to cancer: disappear
  - Basic symptoms: similar
  - Treatment related: new

## Normative Data for the Low Anterior Resection Syndrome Score (LARS Score)

Therese Juul, MHSc, PhD,\* Hossam Elfeki, MD, MSc,\*† Peter Christensen, PhD, DMSc,\* Søren Laurberg, MD, PhD, DMSc,\* Katrine J. Emmertsen, MD, PhD,\*‡ and Palle Bager, MPH, PhD§

Annals of Surgery • Volume 269, Number 6, June 2019

## LARS Scores and Items in the Age Group 50 to 79 Years

Among females in the age group 50 to 79 years, 18.8% had a LARS score  $\geq$ 30, corresponding to "major LARS" (n = 400). Among males in this age group, the proportion was 9.6% (n = 407). The median (IQR) LARS score was 16 (7-26) and 11 (4-22), for females and males, respectively (P < 0.001) (Table 3, Fig. 2).

TABLE 4. LARS Score Items for the Age Group 50–79 Years					
Response (Score Value)	Males, n (%)	Females, n (%)	<b>P</b> *		
Do you ever have occasions when you cannot control you	ur flatus (wind)?				
No, never (0)	193 (47.1%)	128 (31.8%)	< 0.001		
<once (4)<="" per="" td="" wk=""><td>73 (17.8%)</td><td>117 (29.0%)</td><td></td></once>	73 (17.8%)	117 (29.0%)			
>once per wk (7)	144 (35.1%)	158 (39.2%)			
2. Do you ever have any accidental leakage of liquid stool?					
No, never (0)	344 (84.1%)	314 (77.9%)	0.079		
<once (3)<="" per="" td="" wk=""><td>51 (12.5%)</td><td>69 (17.1%)</td><td></td></once>	51 (12.5%)	69 (17.1%)			
>once per wk (3)	14 (3.4%)	20 (5.0%)			
3. How often do you open your bowels?					
>7 per d (4)	3 (0.7%)	2 (0.5%)	0.488		
4-7 per d (2)	21 (5.1%)	15 (3.7%)			
1-3 per d (0)	321 (78.3%)	310 (76.7%)			
<once (5)<="" d="" per="" td=""><td>65 (15.9%)</td><td>77 (19.1%)</td><td></td></once>	65 (15.9%)	77 (19.1%)			
4. Do you ever have to open your bowels again within 1 hor	ur of the last bowel opening?				
No, never (0)	272 (66.7%)	230 (56.9%)	0.011		
<once (9)<="" per="" td="" wk=""><td>95 (23.3%)</td><td>113 (28.0%)</td><td></td></once>	95 (23.3%)	113 (28.0%)			
>once per wk (11)	41 (10.1%)	61 (15.1%)			
5. Do you ever have such a strong urge to open your bowel	s that you have to rush to the toilet?				
No, never (0)	206 (50.5%)	189 (47.0%)	0.001		
<once (11)<="" per="" td="" wk=""><td>153 (37.5%)</td><td>126 (31.3%)</td><td></td></once>	153 (37.5%)	126 (31.3%)			
>once per wk (16)	49 (12.1%)	87 (21.6%)			

## BRISTOLE STOOL CHART BSC: 6-7(loose or watery)

■ 6-7% GENERAL POPULATION

## Bowel problem: colon cancer??


■ National cross-sectional study ( numbers)

Control group: polypectomy for cancer

Questionnaires

## Colon cancer-bowel seq

### Right colon cancer



#### Long-term bowel dysfunction after right-sided

#### hemicolectomy for cancer. A population-based study.

Authors: Helene Mathilde Larsen, BSc<sup>1</sup>, Hossam Elfeki, MD<sup>1,2</sup>, Katrine <u>Jøssing</u>

Emmertsen, MD PhD<sup>1</sup>, and Søren Laurberg, MD DMSc<sup>1</sup>

All Danish colon cancer survivors treated with right-sided hemicolectomy or polypectomy (2001 – 2015) received a questionnaire regarding bowel function and the EORTC QLQ-C30 quality of life questionnaire.

3540 patients (3306 right-sided hemicolectomy and 234 polypectomy) responded - response rate 60.3%.

Bristol stool chart, number (%	5)									
	Type 1	Type 2	Type 3	Type 4	Type 5	Type 6	Type 7	Type 1-5	Type 6-7	Total
Right-sided hemicolectomy	65 (2.1)	411 (13.1)	506 (16.1)	1294 (41.2)	377 (12.0)	392 (12.5)	94 (3.0)	2653 (84.5)	486 (15.5)	3139 (100.0)
Polypectomy	5 (2.2)	35 (15.6)	52 (23.1)	99 (44.0)	19 (8.4)	14 (6.2)	1 (0.4)	210 (93.3)	15 (6.7)	225 (100.0)
Sigmoidectomy+								2821 (95.6)	130 (4.4)	P = 0.001


+Elfeki et al.(15).

Right-sided hemicolectomy: increased risk of long-term bowel

dysfunction, which impair quality of life

## Colon cancer-bowel seq

#### Sigmoid cancer



## Bowel dysfunction after sigmoid resection for cancer and its impact on quality of life

H. Elfeki<sup>1,3</sup>, H. M. Larsen<sup>1</sup>, K. J. Emmertsen<sup>1,2</sup>, P. Christensen<sup>1</sup>, M. Youssef<sup>3</sup>, W. Khafagy<sup>3</sup>, W. Omar<sup>3</sup> and S. Laurberg<sup>1</sup>

BJS 2019; 106: 142-151

A total of 3295 patients (3061 sigmoid resection, 234 polypectomy) responded to the questionnaire (response rate 63.8%)

Conclusion: Sigmoid resection for cancer is associated with an increased risk of long-term bowel dysfunction; obstructed defaecation is prevalent and associated with substantial impairment of QoL.

- 5 symptoms with the greatest differences :
- nocturnal defaecation (32·1 versus 12·6 per cent),
- use of aids during defaecation (24.2 versus 12.2 per cent),
- fragmentation at least weekly (21.5 versus 16.0 per cent),
- daily bloating (20.4 ver- sus 13.5 per cent)
- sense of outlet obstruction at least weekly (14.9 versus 8.2 per cent)

Table 3 Patterns of bowel dysfunction and impact on quality of life after sigmoid resection versus polypectomy

	Sigmoid resection (n = 3061)	Polypectomy (n = 234)	P†	Odds ratio*	Adjusted odds ratio*‡
Obstructed defaecation symptoms BSS score	546 of 3043 (17-9) n = 2951	17 of 232 (7-3) n = 225	< 0.001	2-76 (1-67, 4-57)	2-57 (1-54, 4-26)
1-2	619 (21-0)	40 (17-8)	0.254	1-19 (0-83, 1-70)	
3-5	2202 (74-6)	170 (75-6)	0.765	1-00 (reference)	
6-7	130 (4-4)	15 (6-7)	0-117	0.66 (0.38, 1.16)	
Wexner incontinence score > 9	173 of 3002 (5-8)	7 of 230 (3-0)	0.099	1.94 (0.99, 4.19)	1.75 (0.81, 3.81)
Major LARS	680 of 2993 (22-7)	35 of 226 (15-5)	0.011	1.61 (1.11, 2.33)	1-60 (1-09, 2-34)
Any change in lifestyle for incontinence	687 of 3038 (22-6)	27 of 232 (11·6)	< 0.001	2.21 (1.47, 3.34)	2.09 (1.38, 3.17)
Quality of life	n=3014	n=228	0.008		
Not impaired (no or little impact)	2515 (83-4)	205 (89-9)		1-00 (reference)	
Impaired (some or major impact)	499 (16-6)	23 (10-1)		1.77 (1.14, 2.75)	1.76 (1.13, 2.79)

Values in parentheses are percentages unless indicated otherwise; \*values in parentheses are 95 per cent confidence intervals. BSS, Bristol stool scale; LARS, low anterior resection syndrome.  $\uparrow \chi^2$  test. ‡Adjusted for sex, age and time since treatment.

Table 4 Logistic regression analysis of obstructed defaecation symptoms grouped by number of symptoms

No. of symptoms	Sigmoid resection (n = 3043)	Polypectomy (n = 232)	Crude odds ratio	P
All 6	174 (5-7)	6 (2-6)	2-28 (1-00, 5-21)	0.044
≥5	546 (17-9)	17 (7-3)	2-76 (1-67, 4-57)	< 0.001
≥4	1050 (34-5)	49 (21-1)	1.96 (1.42, 2.72)	< 0.001
≥3	1584 (52-1)	87 (37-5)	1-81 (1-37, 2-38)	< 0.001
≥2	2182 (71-7)	148 (63-8)	1-43 (1-01, 1-90)	0.014


Values in parentheses are 95 per cent confidence intervals.


## TYPE AND %

Right hemicolectomy

Sigmoid resection

About 1: 10 develop diarrhea At least 1:10 develop ODS






### WHY


#### Right hemicolectomy

- Bile malabsorption
- Bacterial overgrowth



#### Sigmoid resection

- Loss rectosigm break
- denervation



# Prospective studies designed based on our experience


#### **Late Sequelae after Colon Cancer**

Annette Bosen Bräuner<sup>1</sup>, Katrine Jøssing Emmertsen<sup>2</sup>, Michael Bødker Lauritzen<sup>3</sup>, Ole Thorlacius-Ussing<sup>3</sup>, Uffe Schou Løve<sup>1</sup>,

Peter Christensen<sup>4</sup>, Søren Laurberg<sup>4</sup>, Klaus Krogh<sup>5</sup>, Asbjørn Drewes<sup>6</sup>, Therese Juul<sup>4</sup>

1. Department of Surgery, Regional Hospital Viborg 2. Department of Surgery, Regional Hospital Randers 3. Department of Surgery, Aalborg University Hospital 4. Department of Surgery, Aarhus University Hospital

5. Department of Hepatology, Aarhus University Hospital 6. Department of Gastroenterology, Aalborg University Hospital




#### Tools included in the survey

Domain	Scores / "ad hoc" single items	Items
Bowel function	Low Anterior Resection Syndrome Score	
	Wexner Incontinence Score	
	St Mark's Incontinence Score	
	Bristol Stool Chart	1
	Patient Assessment of Constipation Symptoms	12
	"Do you take any medicine for constipation?"	1
	"Do you take any fibre supplement?"	
	"Do you have bowel movements during the night?"	
	Colostomy impact score	
	"How would you evaluate your bowel function over the past 4 weeks?"	1
	"Overall, how much does your bowel function affect your quality of life?"	1
Diet 6 ad hoc questions regarding diet		6
	Memorial Sloan Kettering Cancer Center Bowel Function Index (dietary scale)	4
Quality of life	Quality of life European Quality of Life – 5 Dimensions	
	"Overall how would you evaluate your quality of life over the past 4 weeks?"	1
Missing items	"Do you have any late sequelae from your bowel cancer treatment that are NOT covered in this guestionnaire?"	
Need for treatment	"Do you wish to be contacted to discuss possibilities for treatment of any late sequelae?"	

#### Results

All inclusions, completed surveys and refferals (16/4 2018-15/8 2019)



- Systematic screening for late sequelae after colon cancer using ePROMs is an effective method to identify patients in need for further treatment
- 9% were referred to treatment for severe late sequelae

# BUT: can we do anything???

yes

## Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer

H Jervoise N Andreyev, <sup>1</sup> Susan E Davidson, <sup>2</sup> Catherine Gillespie, <sup>3</sup> William H Allum, <sup>1,4</sup> Edwin Swarbrick <sup>5</sup>

Gut 2012;61:179—192. doi:10.1136/gutjnl-2011-300563

#### **Key facts**

- There has been a threefold increase in the numbers of survivors of cancer in the last 30 years
- Chronic gastrointestinal side effects are a common cause of morbidity and reduced quality of life
- Side effects of treatment are frequently missed or overlooked because the current priority of cancer follow-up is to perform surveillance for recurrent cancer
- Individual GPs are unlikely to have many patients with complex problems after cancer therapy and so will require guidance if these patients are to be optimally managed
- Symptoms can often be alleviated or cured.

Clinical evaluation and treatment of chronic bowel symptoms following cancer in the colon and pelvic organs

Helene Mathilde Larsen, Mette Borre, Peter Christensen, Asbjørn Mohr
Drewes, Søren Laurberg, Klaus Krogh & Janne Fassov

ACTA ONCOLOGICA
2019, VOL. 58, NO. 5, 776–781

60 patients: cancer in the right colon:31, sigmoid colon 1, rectum 14, anal canal 4, cervix uteri 5, corpus uteri 2, ovary2, and prostate 1.

frequent bowel movements (65%), loose stools (87%), urgency (57%), and incontinence (50%).

A specific cause was found in 48 (80%) and 21 (35%) had more than one cause

Most patients will benefit from expert clinical evaluation and targeted treatment.

Table 3. Results of diagnostic tests.

	Breat	th test	SeHCAT retention			
	Positive	Negative	<10%	10-15%	Normal (>15%)	
All cancers, n=60	32	15	29	6	8	
Right colon, $n=31$	20	6	14	4	3	
Sigmoid colon, $n = 1$	-	-	1	-	_	
Rectum, n=14	7	4	6	-	5	
Anal canal, $n=4$	1	2	3	1	_	
Cervix uteri, n=5	2	1	3	-	_	
Corpus uteri, n=2	1	1	1	1	_	
Ovary, n=2	1	-	1	-	-	
Prostate, n=1	-	1	-	-	_	

Data are presented as numbers. SeHCAT: Selenium-75 homocholic acid taurine.

Table 4. Treatment modalities used in our clinic.

Treatment modalities	
	n (%)
Antibiotics	
Ciprofloxacin	28 (47)
Rifaximin	13 (22)
Other <sup>a</sup>	7 (12)
Bile acid sequestrants	
Cholestyramine	31 (52)
Colesevelam	19 (32)
Both	14 (23)
Loperamide	21 (35)
Laxative	9 (15)
Dietary intervention <sup>b</sup>	20 (33)
Stoma	2 (3)

<sup>&</sup>lt;sup>a</sup>Amoxicillin (n = 4), metronidazole (n = 3).

<sup>&</sup>lt;sup>b</sup>Fat and/or fiber reducing regimen.

# Update to day treatment bowel symptoms

- 64 cases right hemicolectomy
- 42 evaluated and treated
  - 35 major effect
  - 7 some effect
  - 0 no effect

## PRESENT STRATEGY crc

- All patients are followed by proms
  - Bowel, bladder, sex, pain
  - Response rate >80%
- Offered standardised treatment
  - Colon and bowel: 10%
- Trials-and evaluation
  - Colon cancer and bowel: rewarding